Board of Directors
Shefali AGARWAL, MD
Before joining Onxeo, Dr. Shefali Agarwal was Chief Medical Officer at Epizyme, Inc., a clinical-stage company developing novel epigenetic therapies for cancer and other serious diseases, where she leads the global clinical development and regulatory strategy for tazemetostat for the treatment of cancer. Prior to joining Epizyme in 2018, Dr. Agarwal held leadership positions across medical research, clinical development, clinical operations and medical affairs. She most recently served as chief medical officer at SQZ Biotech, where she built and led the clinical development organization, which included clinical research operations and the regulatory function. Before SQZ Biotech, Dr. Agarwal also held leadership positions at Curis and Tesaro. At Curis, she oversaw the Phase 2 study for its dual HDAC/PI3K inhibitor in diffuse large B-cell lymphoma, and the Phase 1 study in solid tumors for its oral checkpoint inhibitor. At Tesaro, she led the NDA and EMA submissions for ZEJULA(r) (niraparib) in ovarian cancer. Dr. Agarwal has also held positions of increasing responsibility at Covidien, AVEO Oncology and Pfizer. In addition to receiving her medical degree, Dr. Agarwal holds a master’s of public health and a master’s of science in business.
Shefali AGARWAL, MDPRESIDENT AND CHIEF EXECUTIVE OFFICER
Khalil Barrage is a Managing Director at Invus, based in New York.
He joined Invus in 2003 and established its Public Equity activity. Since its inception, Invus Public Equity has concentrated its investments in the emerging innovative biotech companies. Prior to joining Invus, he worked at The Olayan Group in New York and ran their US equity portfolio for 15 years. He holds a BA in Economics from the American University of Beirut.
He is a member of the board of several biotechs including Celtaxsys and Protagenic Therapeutics in the US and Sensorion in France. Shareholders also approved the renewal of the term of office of Board member GammaX Corporate Advisory, represented by Mr. Jacques Mallet, for an additional 3-year term.
Khalil BARRAGEDIRECTOR - REPRESENTING INVUS
Robert L. COLEMAN
Robert L. Coleman, MD, is the Chief Scientific Officer of US Oncology Research, one of the U.S. largest networks dedicated to advancing high-quality, evidence-based cancer care and research, with more than 400 clinical studies underway and gathering over 1400 physicians. Prior to joining the US Oncology Network in 2020, Dr Coleman served as executive director of MD Anderson's Cancer Network Research Program. Additionally, he was a professor and also served as the Ann Rife Cox Chair in Gynecology at The University of Texas. Dr Coleman's work has been featured in over 500 publications focusing on the role of novel therapies in ovarian cancer, such as the incorporation of PARP inhibitors in the treatment strategy.
Robert L. COLEMANINDEPENDENT DIRECTOR
Bryan Giraudo is both the Chief Operating Officer & Chief Financial Officer of Gossamer Bio, a U.S. listed biopharmaceutical company (Nasdaq: GOSS) focused on developing and commercializing innovative therapeutics in the areas of immunology, inflammation and oncology.
Previously, he served as Senior Managing Director at LEERINK Partners, where he was responsible for LEERINK’s Western North America and Asia life sciences investment banking practice. Prior to joining LEERINK Partners in 2009, Mr Giraudo was a Managing Director in Merrill Lynch’s Global Healthcare Investment Banking Division.
Bryan GIRAUDOINDEPENDENT DIRECTOR
Jacques Mallet, MD, served as SVP - Head of Portfolio Analytics/Corporate Strategy and Member of the Executive Leadership Team of Sanofi and is currently board member of several listed or private companies in the health technology sector. He brings to Onxeo more than 30 years of pharmaceutical industry experience within R&D, Pipeline Development and Corporate Strategy and a unique insight gained in life sciences both in Europe and the United States as a venture capitalist. Prior to this, Mr Mallet had been responsible for investments at Auriga Partners, a key life sciences specialized private-equity firm in France, and held executive positions in global consulting firms such as Monitor Deloitte and Accenture.
Jacques MALLETINDEPENDENT DIRECTOR
Julien Miara is a Principal at Invus. He joined in 2010 as an analyst in the Public Equity group, covering Biotechnology among other sectors.
Since 2018, Julien leads the team in Europe. Previously, he worked in investment banking at BNP Paribas in Paris and Société Générale in New-York, as well as in management consulting. Julien Miara received his Master of Management from EDHEC Business School in Lille (France) in 2009.
At its meeting on September 17, 2020, the Board of Directors of Onxeo co-opted Mr. Julien Miara as a director of the Company. This cooptation was ratified by the Company’s ordinary general meeting of June 10, 2021.
Mr. Julien Miara was appointed as interim CEO of Onxeo on January 3, 2022.
Julien MIARADIRECTOR - REPRESENTING INVUS
He began his career as Deputy Chief Financial Officer at Total in Cameroon in 1990 and then as Financial Auditor at Ernst & Young on various missions in the industrial and financial sectors.
He then moved to the pharmaceutical industry where, from 1996 to 2006, he held positions of increasing responsibility within the finance division of Pfizer France: first in charge of the treasury and internal audit as Director of Treasury, Tax and Audit. In this position, he was responsible in particular for financial risk management for the French subsidiaries of Pfizer and he managed the financial implementation of various restructuring operations (including two mergers, one with Warner-Lambert in 2000 and then Pharmacia in 2003) as well as the implementation of tax and financial optimisation schemes.
Nicolas Fellmann is a graduate of Lyon Graduate School of Management (EM Lyon).
Nicolas FELLMANNCHIEF FINANCIAL OFFICER
Olivier de BEAUMONT
Olivier de BEAUMONTCHIEF MEDICAL OFFICER
Audrey Legentil-Duméry worked as a Senior HR consultant with a Paris-based agency, managing HR on behalf of diverse companies, notably accompanying SME’s through periods of growth and transition.
Ms. Legentil-Duméry successfully conducted several missions in the pharma and biotech sectors.
Audrey Legentil-Duméry holds a Magister and a Master in Management and Intercultural Communication from CELSA (Sorbonne, Paris).